Abstract Purpose: Sintilimab, as a domestically produced innovative immune checkpoint inhibitor (ICIs) drug, performs well in the treatment of lung cancer. However, due to the late start of domestically produced ICIs, Sintilimab is currently only available for domestic use, with limited clinical data and facing challenges in post-marketing evaluation. It is planned to use Meta analysis methods to evaluate its safety and effectiveness. Methods: Computerized searches were conducted on various databases from their inception to August 10, 2023. Meta-analysis was carried out using RevMan 5.4 software after two evaluators independently screened the literature, extracted information, and evaluated the risk of bias in the included studies. Results: The results indicated that patients with advanced NSCLC receiving Sintilimab had a 5.14 times higher risk of hypothyroidism compared to the control group. Hematologic toxicity and hepatic impairment were not significantly different from the chemotherapy group, while gastrointestinal and alopecia adverse reactions may be less frequent than in the chemotherapy group. Additionally, the risk of pneumonia, proteinuria, rash, and infusion reaction may be increased. Furthermore, Sintilimab combined with chemotherapy was found to enhance ORR, DCR, and prolong mOS and mPFS in NSCLC patients. Conclusion: Sintilimab in combination with chemotherapy for advanced NSCLC is efficacious, safe and manageable.
No takes yet. Share an insight, caveat, or question.
Pan et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: